Financial Performance - In Q3 2025, the new generation of orthokeratology lenses accounted for 4.23% of total hard lens revenue for the first three quarters, increasing to 9.68% in Q3, indicating continuous growth [2] - The overall gross margin for hard lenses decreased by 0.23% year-on-year for the first three quarters and by 0.56% in Q3 [5] - The revenue from scleral lenses represented 1.21% of hard lens income in the first three quarters, slightly increasing to 1.22% in Q3 [3] Product Development and Market Strategy - The company is focusing on the development and promotion of new and specialty products to gain competitive advantages in the hard lens market [2] - The company has launched a range of soft contact lenses, including daily and monthly disposable colored lenses, with production quality reaching 85% [4] - The company plans to create a product matrix for myopia control, including orthokeratology lenses, multifocal soft lenses, and composite frame lenses [4] Sales and Marketing - The company has seen an 8.42% year-on-year increase in revenue from optical service centers, which now account for 57.4% of total revenue, up from 53.01% in the previous year [8] - The company is implementing a pricing strategy that balances competitiveness and brand value, avoiding price wars while promoting affordable options [7] - The company has developed a range of eye care products, including eye wash and nebulization solutions, to expand its product offerings [5] Research and Development - The company is actively developing a variety of products, including new lens types, pharmaceuticals, and eye health products, with several in clinical trials [9] - The company has registered new products such as low-concentration atropine and other eye drops targeting myopia and presbyopia [6] - The company is also exploring smart glasses in collaboration with technology partners, focusing initially on audio-enabled models [7]
欧普康视(300595) - 2025年10月27日投资者关系活动记录表